Cytokinetics INC Form 4 insider transactions

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, exercised stock options and subsequently sold an equal number of shares on June 17, 2025, under a Rule 10b5-1 trading plan.

Robert I. Blum, President and CEO of Cytokinetics Inc., has sold 5,000 shares of common stock at $33.8 per share, executed under a Rule 10b5-1 trading plan.

Edward M. Kaye, a Director at Cytokinetics Inc. (CYTK), has sold 3,636 shares of common stock at a price of $32.1 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 8,659 shares of common stock for $32.04 per share on June 5, 2025, under a Rule 10b5-1 trading plan.

Fady Ibraham Malik, EVP Research & Development at Cytokinetics Inc., executed a pre-planned transaction on June 3, 2025, exercising stock options and simultaneously selling an equal number of common shares.

Cytokinetics' Executive Vice President and Chief Financial Officer, Lee Sung, reported a routine disposition of 4,965 shares of common stock for tax withholding purposes following the vesting of restricted stock units.

Cytokinetics Inc.'s President and CEO, Robert I. Blum, reported the sale of 5,000 shares of common stock for approximately $156,100, executed under a Rule 10b5-1 trading plan.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on May 20, 2025.

Director Robert Harrington reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Cytokinetics' President and CEO, Robert I. Blum, sold 5,000 shares of common stock at a price of $30.93 on May 16, 2025.

Director Muna Bhanji reported selling 1,454 shares of Cytokinetics Inc. common stock on May 15, 2025.

Director Lynne Parshall reports acquisition of restricted stock units and stock options in Cytokinetics, along with disposition of common stock.

Director Muna Bhanji reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Director John T. Henderson reports acquisition of Cytokinetics stock and options, including restricted stock units and non-qualified stock options, as per Form 4 filing.

Director Edward M. Kaye reports acquisition of Cytokinetics stock and options, signaling changes in beneficial ownership.

Director Robert E. Landry reports the acquisition of restricted stock units and stock options in Cytokinetics Inc.

Director Wendell Wierenga reports acquisition of Cytokinetics stock and options, including restricted stock units and non-qualified stock options, as per Form 4 filing.

Director Nancy Wysenski reports the acquisition of restricted stock units and stock options in Cytokinetics, Inc.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on May 6, 2025.

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, sold 4,002 shares of common stock at a price of $36.68 on May 5, 2025.

Cytokinetics CEO Robert Blum sold 5,000 shares of common stock at a price of $40.96 on April 29, 2025, according to a Form 4 filing.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the exercise of stock options and subsequent sale of shares on April 22, 2025.

Wendall Wierenga, a director at Cytokinetics Inc, exercised stock options and sold shares on April 21, 2025, according to a recent SEC filing.

Director John T. Henderson exercised stock options and sold a portion of the acquired shares of Cytokinetics Inc. on April 15, 2025.

Director John T. Henderson acquired 551 shares of Cytokinetics Inc. common stock at $38.56 per share in lieu of a cash retainer.

Director Robert Arthur Harrington acquired 324 shares of Cytokinetics Inc. common stock at $38.56 per share through the Director Stock in lieu of Cash Retainer Plan.

Edward M. Kaye, a director at Cytokinetics Inc, acquired 324 shares of common stock through the Director Stock in lieu of Cash Retainer Program on April 15, 2025.

Director Wendell Wierenga acquired 162 shares of Cytokinetics Inc. common stock on April 15, 2025, through the Director Stock in lieu of Cash Retainer Program.

Director Nancy Wysenski acquired 162 shares of Cytokinetics Inc. common stock through the Director Stock in lieu of Cash Retainer Program.

Cytokinetics' President and CEO, Robert I. Blum, sold 5,000 shares of common stock at a price of $36.77 on April 10, 2025.